Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Starling OncologySTLN +5.56%56 Forward PE Ratio is 0.00 as of Aug. 05, 2026. GuruFocus rates STLN with a GF Score™ of 56/100 and a GF Value™ of $2.29 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 313 Healthcare Providers & Services companies, Starling Oncology ranks worse than 319488.5% on this metric.
Starling Oncology (NAS:STLN) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Starling Oncology Forward PE Ratio Related Terms
Starling Oncology Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Starling Oncology's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starling Oncology Forward PE Ratio Chart
Starling Oncology Annual Data
Trend
Forward PE Ratio
Starling Oncology Quarterly Data
Forward PE Ratio
STLN vs SRTA, CCRN, CYH: Forward PE Ratio Comparison
For the Medical Care Facilities subindustry, Starling Oncology's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starling Oncology Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Starling Oncology's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Starling Oncology's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Starling Oncology (STLN) has a Forward PE Ratio of 0.00 as of Aug. 05, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Starling Oncology and its competitors. According to the industry distribution chart, Starling Oncology ranks #999999 out of 313 companies in the Healthcare Providers & Services industry.
Is Starling Oncology's Forward PE Ratio too high?
Starling Oncology's current Forward PE Ratio is 0.00. Based on the distribution chart, Starling Oncology ranks #999999 out of 313 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Starling Oncology has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's Forward PE Ratio compare to SRTA and CCRN?
According to the Healthcare Providers & Services industry distribution chart, Starling Oncology ranks #999999 out of 313 companies for Forward PE Ratio. This places Starling Oncology in the lower half of its industry. The industry median Forward PE Ratio is 18.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.40, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Starling Oncology and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starling Oncology's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Based on GuruFocus' analysis, Starling Oncology (STLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.29, compared to a current price of $5.17 — trading 125.8% above its estimated fair value. The current Forward PE Ratio is 0.00. Starling Oncology's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Starling Oncology (STLN), the current Forward PE Ratio is 0.00 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starling Oncology (STLN) Overvalued in 2026?
Based on GuruFocus' analysis, Starling Oncology stock appears to be overvalued.
The current stock price of $5.17 is trading 125.8% above its estimated GF Value™ of $2.29.
GuruFocus considers Starling Oncology to be Significantly Overvalued.
Key valuation signals for STLN:
Forward PE Ratio: 0.00
GF Value™: $2.29 vs. price of $5.17 (125.8% above fair value)
No single metric tells the full story. See the STLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for STLN
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STLN has been successfully added to your 
